Dr. Kosmider is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 Colchester Ave
Burlington, VT 05401Phone+1 802-847-0000
Education & Training
- University of Vermont Medical CenterResidency, Anesthesiology, 2021 - 2025
- Western University of Health Sciences College of Osteopathic Medicine of the Pacific-NorthwestClass of 2021
- Northeastern UniversityBS, Biology, Cum Laude, 2010 - 2014
Awards, Honors, & Recognition
- Anesthesiology Clinical Specialty Award Western University of Health Sciences, 2021
Publications & Presentations
PubMed
- 604 citationsOvercoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cellsOlivier De Henau, Matthew Rausch, David W. Winkler, Luis Felipe Campesato, Cailian Liu
Nature. 2016-11-17 - 24 citationsThe phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.Kerrie Faia, Kerry White, Erin Murphy, Jennifer L. Proctor, Melissa Pink
Plos One. 2018-08-01
Abstracts/Posters
- Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell linesWhite K, Murphy E, Faia K, Proctor J, Kosmider N, Pink M, Goldstein S, McGovern K, Kutok J., AACR 107th Annual Meeting, New Orleans, LA, 4/16/2016
- Checkpoint Blockade Therapy is Improved by Altering the Immune Suppressive Microenvironment with IPI-549, a Potent and Selective Inhibitor of PI3K-gamma, in Preclinica...Henau O, Merghoub T, Winkler D, Sharma S, Pink M, Tchaicha J, Rausch M, Proctor J, Kosmider N, Soglia J, Palombella V, Kutok J, Wolchok J, McGovern K, AACR 107th Annual Meeting, New Orleans, LA, 4/16/2016
- The Potent and Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor, IPI-549, Inhibits Tumor Growth in Murine Syngeneic Solid Tumor Models through Alterations in the...Kutok J, Ali J, Brophy E, Castro A, DiNitto J, Evans C, Faia K, Goldstein S, Kosmider N, Lescarbeau A, Liu T, Martin C, McGovern K, Nair S, Pink M, Proctor J, Rausch M..., American Association for Cancer Research Inaugural International Cancer Immunotherapy Conference, Boston, MA, 11/5/2015
Other
- Patent: Compositions and Methods for ImmunotherapyKosmider, N, inventor; Obsidian Therapeutics, assignee
https://patentscope.wipo.int/search/en/detail.jsf?docId=EP280242257&_cid=P21-K9VQCK-72395-1
European Patent Office - 1/8/2020 - Patent: CD19 Compositions and Methods for ImmunotherapyKosmider, N, inventor; Obsidian Therapeutics, assignee.
https://patentscope.wipo.int/search/en/detail.jsf?docId=EP280242559&_cid=P21-K9VQCK-72395-1
European Patent Office - 1/1/2020 - Patent: CD19 Compositions and Methods for ImmunotherapyKosmider, N, inventor; Obsidian Therapeutics, assignee.
https://patentscope.wipo.int/search/en/detail.jsf?docId=IN276071677&_cid=P21-K9VQCK-72395-1
India Patent Office - 11/1/2019 - Join now to see all
Professional Memberships
- American Society of AnesthesiologistsResident Delegate, Medical Student Delegate
External Links
- LinkedInhttps://www.linkedin.com/in/nicole-kosmider/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: